Dier Mardi, an insider at Madrigal Pharmaceuticals Inc (MDGL), executed a sale of 13,529 shares on December 1, 2025, at a price of $573.02 per share, totaling approximately $7.75 million. Following this transaction, Mardi retains 13,529 shares in the company.
Madrigal Pharmaceuticals, which specializes in developing innovative therapies for cardiovascular, metabolic, and liver diseases, has a market capitalization of $13.3 billion. The company’s flagship product, Rezdiffra (resmetirom), is a once-daily oral medication approved by the FDA for treating nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis.
Insider selling can stem from various motivations, including diversification, tax planning, or personal financial needs. While significant selling activity may attract investor scrutiny, it does not necessarily reflect negative sentiment towards the company. Investors are encouraged to consider insider transactions within a broader context, examining patterns over time and across multiple insiders rather than focusing on isolated events.
Madrigal Pharmaceuticals is set to report its next earnings on April 29, 2026, with an estimated EPS of -$0.39 and revenue expectations of $317.1 million. This update provides insight into how company executives engage with their stock, but such transactions should be viewed alongside other fundamental and technical factors.